Avicena to Present at 4th Annual BIO InvestorForum Conference
October 08 2007 - 6:43PM
PR Newswire (US)
Expansion of Drug Pipeline and Advancement of Clinical Programs
PALO ALTO, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Avicena Group,
Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) , a late-stage biotechnology
company that develops central nervous system therapeutics for
neurodegenerative disorders, announced today that it will be a
presenting company at the 4th Annual BIO InvestorForum Conference
to be held October 9-11, 2007 at the Palace Hotel of San Francisco.
The company's chief executive officer, Belinda Tsao-Nivaggioli,
Ph.D., will present an overview of the company and its clinical
programs, including an update on activities to build its drug
pipeline and investigate new delivery vehicles to enhance the
bioavailability of its lead drug candidates. Dr. Tsao-Nivaggioli
will be presenting on Thursday, October 11 at 10:30 a.m. (EDT) in
the Twin Peaks North room. For more information on this event
please visit: http://www.investorforum.bio.org/. To participate in
a live audio and visual webcast of Dr. Tsao-Nivaggioli's
presentation please log onto Avicena's corporate website at
http://www.avicenagroup.com/ at least fifteen minutes prior to the
start of the presentation to download any necessary materials. An
archive of this event will be available in the investor relations
section of the website for 30 days. ABOUT AVICENA Avicena Group,
Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) is a Palo Alto, California
based late stage biotechnology company that develops central
nervous system therapeutics for neurodegenerative diseases. The
company's core technologies, supported by a robust IP portfolio,
have broad applications in both pharmaceuticals and dermaceuticals.
Avicena's pharmaceutical program centers on rare neurological
disorders (orphan diseases). Near term, the company plans to
initiate a confirmatory Phase III trial in ALS and a Phase III
trial in Huntington's disease to accompany the ongoing NIH Phase
III trail in Parkinson's disease. Avicena's science is well
established and its products are safe and well tolerated. Unlike
traditional biotechnology companies, Avicena's clinical programs
are largely funded by government and non-profit organizations.
Avicena presently derives revenue from the sale of proprietary
dermaceutical ingredients to skin care manufacturers. Contact: The
Ruth Group (on behalf of Avicena Group) Sara Ephraim (investors)
(646) 536-7002 Janine McCargo / Jason Rando (media) (646) 536-7033
/ 7025 or DATASOURCE: Avicena Group, Inc. CONTACT: Sara Ephraim
(investors), +1-646-536-7002, , or, media, Janine McCargo,
+1-646-536-7033, , or Jason Rando, +1-646-536-7025, , all of The
Ruth Group, for Avicena Group, Inc. Web site:
http://www.avicenagroup.com/ http://www.investorforum.bio.org/
Copyright